Series A · $50M Target · USD-Denominated

Investor Relations

Building Africa's cancer intelligence infrastructure — raising $50M to deploy at continental scale.

Disclaimer: All financial figures are internal projections. They do not represent current operating results or constitute a guarantee of future performance.

Key Metrics

$50M
Series A Target
77%
Gross Margin / Scan
1.4B+
Addressable Lives
Y2 Q2
EBITDA Positive

Financial Projections

5-Year Revenue vs Costs vs EBITDA (USD Millions) 140 105 70 35 0 $131M $60M $72M Year 1 Year 2 Year 3 Year 4 Year 5 ★ EBITDA+ Year 2 Q2 Revenue Operating Costs EBITDA All figures USD · Internal projections
Scan Economics per Encounter 77% Gross Margin Gross Profit $16–$27 Cost $8.10/scan
$50M Series A Deployment $50M Series A Devices 40% Platform 25% Fleet 15% Team 10% Reg+WC 10%

5-Year Revenue Table

YearRevenue (USD)EBITDAEBITDA MarginMilestone
Year 1$4.9M($0.7M)SA pilot live. First insurer billing.
Year 2$14.8M$2.9M20%EBITDA positive Q2. SADC entry begins.
Year 3$37.5M$17.2M46%Multi-cancer devices. Enterprise SaaS live.
Year 4$74.6M$38.1M51%IPO preparation. Pharma licensing.
Year 5$131.4M$71.9M55%+JSE IPO / NASDAQ ADR / strategic sale.

$50M Deployment

CategoryAmount%Purpose
📱 Devices$20M40%200+ iBreastExam™ units. Revenue from Month 1.
🧠 Platform & AI$12.5M25%MedOS™ + MedIntelligence™ + HealthPass™.
🚐 Pink Pulse™$7.5M15%25 mobile units: vehicles, fit-out, solar, satellite.
👥 Executive Team$5M10%CMO, CTO, CFO, CCO, COO.
⚖️ Regulatory$2.5M5%SAHPRA, MCAZ, CDH across 3 countries.
🏦 Working Capital$2.5M5%18+ months buffer. No second raise needed.

Exit Scenarios

JSE Main Board IPO
R2.8B ~$151M
Year 4–5 · 11–15× on $50M · Primary exit path
Strategic Acquisition
$350M–$600M
Year 3–4 · Data premium · Pharma / Big Tech buyer
NASDAQ ADR
~$3.4B
Year 5–6 · Up to 68× · Health data SaaS multiples

Investor Resources

📊

Pitch Deck

Full 15-slide Series A investor presentation. Available to qualified investors.

Request Access
📈

Financial Model

5-year quarterly projections. Revenue mix. Unit economics. Sensitivity analysis.

Request Access
📋

Investor Brief 2.0

USA-targeted executive brief. All figures USD. Full addendum pack included.

Request Access
Qualified institutional investors may request the full data room via investors@mandierahealth.tech

Contact Investor Relations

📧 investors@mandierahealth.tech

+27 76 655 1456 (WhatsApp)

Atrium on 5th, 5th Street, Sandton 2196, Johannesburg

QR code to contact
Scan to open investor contact